Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 2, 2008, Pages 135-141

  Taketomi, Taro ^a   Szlam, Fania ^a   Bader, Stephen O ^a   Sheppard, Chelsea A ^a   Levy, Jerrold H ^a   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrinolysis; Thrombelastography; Thrombin generation; Thrombin activatable fibrinolysis inhibitor; Tissue plasminogen activator

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; FEEDBACK SYSTEM; FIBRIN FORMATION; HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOELASTOGRAPHY;

ANTIFIBRINOLYTIC AGENTS; CARBOXYPEPTIDASE U; FACTOR VIIA; FIBRINOLYSIS; HUMANS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 39149143971     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282f41e6d     Document Type: Article

References (30)

1. Wolberg AS, Allen GA, Monroe DM, Hedner U, Roberts HR, Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131:645-655.
2. Tanaka KA, Szlam F, Levy JH. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation. Br J Haematol 2006; 134:77-82.
3. Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. Blood 1984; 63:1393-1401.
4. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323-2327.
5. Sorensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2:102-110.
6. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3:2039-2043.
7. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100:1781-1785.
8. Taketomi T, Szlam F, Vinten-Johansen J, Levy JH, Tanaka KA. Thrombin-activated thrombelastography (TEG®) for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagul Fibrinolysis 2007; 18:761-767.
9. Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83:589-591.
10. Tanaka K, Szlam F, Katori N, Sato N, Vega J, Levy J. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg 2004; 99:1283-1289.
11. Sniecinski RM, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA. Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass Anesth Analg 2007; 160 (in press).
12. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56:603-609.
13. Wielders SJH, Beguin S, Hemker HC, Lindhout T. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol 2004; 24:1138-1142.
14. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.
15. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815-3823.
16. Fogelson AL, Tania N. Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 2005; 34:91-108.
17. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11:504-509.
18. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.
19. Taketomi T, Szlam F, Levy JH, Tanaka KA. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII Blood Coagul Fibrinolysis 2007 (in press).
20. Tanaka KA, Szlam F, Vinten-Johansen J, Cardin AD, Levy JH. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thromb Haemost 2005; 94:808-813.
21. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26:2445-2453.
22. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Med Rev 1993; 7:78-83.
23. Bern MM, Sahud M, Zhukov O, Qu K, Mitchell W Jr. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005; 11:20-25.
24. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3:465-468.
25. Dirkmann D, Hanke AA, Gorlinger K, Peters J. Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects. Acta Anaesthesiol Scand 2007; 51:640-643.
26. Ogawa T, Verhamme IM, Sun M-F, Bock PE, Gailani D. Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX. J Biol Chem 2005; 280:23523-23530.
27. Leurs J, Wissing B-M, Nerme V, Schatteman K, Bjorquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89:264-271.
28. Sixma JJ, van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 1984; 58:741-753.
29. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108:3053-3060.
30. Lisman T, de Groot PG, Lambert T, Rojkjaer R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 1:2175-2178.